These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 12742279

  • 1. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.
    Petersen P, Grind M, Adler J, SPORTIF II Investigators.
    J Am Coll Cardiol; 2003 May 07; 41(9):1445-51. PubMed ID: 12742279
    [Abstract] [Full Text] [Related]

  • 2. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
    Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A, SPORTIF Executive Steering Committee for the SPORTIF V Investigators.
    JAMA; 2005 Feb 09; 293(6):690-8. PubMed ID: 15701910
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC, Executive Steering Committee of the SPORTIFF III and V Investigators.
    Cerebrovasc Dis; 2006 Feb 09; 21(4):279-93. PubMed ID: 16449807
    [Abstract] [Full Text] [Related]

  • 5. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
    Ford GA, Choy AM, Deedwania P, Karalis DG, Lindholm CJ, Pluta W, Frison L, Olsson SB, SPORTIF III, V Investigators.
    Stroke; 2007 Nov 09; 38(11):2965-71. PubMed ID: 17885258
    [Abstract] [Full Text] [Related]

  • 6. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
    Olsson SB, Executive Steering Committee of the SPORTIF III Investigators.
    Lancet; 2003 Nov 22; 362(9397):1691-8. PubMed ID: 14643116
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Preventing stroke in atrial fibrillation: the SPORTIF programme.
    Lip GY.
    Pathophysiol Haemost Thromb; 2005 Nov 22; 34 Suppl 1():25-30. PubMed ID: 15812201
    [Abstract] [Full Text] [Related]

  • 10. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL, Executive Steering Committee, SPORTIF III and V Study Investigators.
    Am Heart J; 2003 Sep 22; 146(3):431-8. PubMed ID: 12947359
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
    Kulbertus H.
    Rev Med Liege; 2003 Dec 22; 58(12):770-3. PubMed ID: 14978854
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators.
    Am Heart J; 2006 Nov 22; 152(5):967-73. PubMed ID: 17070169
    [Abstract] [Full Text] [Related]

  • 16. Ximelagatran in prevention of cardiovascular events.
    Molckovsky D, Boucher M.
    Issues Emerg Health Technol; 2004 Nov 22; (62):1-4. PubMed ID: 15565751
    [Abstract] [Full Text] [Related]

  • 17. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
    Reiffel JA.
    Curr Opin Cardiol; 2004 Jan 22; 19(1):58-63. PubMed ID: 14688636
    [Abstract] [Full Text] [Related]

  • 18. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.
    Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Colwell CW.
    Ann Intern Med; 2002 Oct 15; 137(8):648-55. PubMed ID: 12379064
    [Abstract] [Full Text] [Related]

  • 19. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL.
    Expert Rev Cardiovasc Ther; 2004 Mar 15; 2(2):163-74. PubMed ID: 15151465
    [Abstract] [Full Text] [Related]

  • 20. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL.
    Rev Cardiovasc Med; 2004 Mar 15; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.